OBJECTIVE: To describe the accuracy of SLN mapping in patients with a preoperative diagnosis of grade 1 endometrial cancer. METHODS: A prospective, non-randomized study of women with a preoperative diagnosis of endometrial cancer and clinical stage I disease was conducted. A subset analysis of patients with a preoperative diagnosis of grade 1 endometrial endometrioid cancer was performed. All patients had preoperative lymphoscintigraphy with Tc99m on the day of or day before surgery followed by an intraoperative injection of 2 cm(3) of isosulfan or methylene blue dye deep into the cervix or both cervix and fundus. All patients underwent hysterectomy, bilateral salpingo-oophorectomy, and regional nodal dissection. Hot and/or blue nodes were labeled as SLNs and sent for histopathological analysis. RESULTS: Forty-two patients with a preoperative diagnosis of grade 1 endometrial carcinoma treated from 3/06 to 8/08 were identified. Twenty-five (60%) had laparoscopic surgery; 17 (40%) were treated by laparotomy. Preoperative lymphoscintigraphy visualized SLNs in 30 patients (71%); intraoperative localization of the SLN was possible in 36 patients (86%). A median of 3 SLNs (range, 1-14) and 14.5 non-SLNs (range, 4-55) were examined. In all, 4/36 (11%) had positive SLNs-3 seen on H&E and 1 as cytokeratin-positive cells on IHC. All node-positive cases were picked up by the SLN; there were no false-negative cases. The sensitivity of the SLN procedure in the 36 patients who had an SLN identified was 100%. CONCLUSION: Sentinel lymph node mapping using a cervical injection with combined Tc and blue dye is feasible and accurate in patients with grade 1 endometrial cancer and may be a reasonable option for this select group of patients. Regional lymphadenectomy remains the gold standard in many practices, particularly for the approximately 15% of cases with failed SLN mapping.
OBJECTIVE: To describe the accuracy of SLN mapping in patients with a preoperative diagnosis of grade 1 endometrial cancer. METHODS: A prospective, non-randomized study of women with a preoperative diagnosis of endometrial cancer and clinical stage I disease was conducted. A subset analysis of patients with a preoperative diagnosis of grade 1 endometrial endometrioid cancer was performed. All patients had preoperative lymphoscintigraphy with Tc99m on the day of or day before surgery followed by an intraoperative injection of 2 cm(3) of isosulfan or methylene blue dye deep into the cervix or both cervix and fundus. All patients underwent hysterectomy, bilateral salpingo-oophorectomy, and regional nodal dissection. Hot and/or blue nodes were labeled as SLNs and sent for histopathological analysis. RESULTS: Forty-two patients with a preoperative diagnosis of grade 1 endometrial carcinoma treated from 3/06 to 8/08 were identified. Twenty-five (60%) had laparoscopic surgery; 17 (40%) were treated by laparotomy. Preoperative lymphoscintigraphy visualized SLNs in 30 patients (71%); intraoperative localization of the SLN was possible in 36 patients (86%). A median of 3 SLNs (range, 1-14) and 14.5 non-SLNs (range, 4-55) were examined. In all, 4/36 (11%) had positive SLNs-3 seen on H&E and 1 as cytokeratin-positive cells on IHC. All node-positive cases were picked up by the SLN; there were no false-negative cases. The sensitivity of the SLN procedure in the 36 patients who had an SLN identified was 100%. CONCLUSION: Sentinel lymph node mapping using a cervical injection with combined Tc and blue dye is feasible and accurate in patients with grade 1 endometrial cancer and may be a reasonable option for this select group of patients. Regional lymphadenectomy remains the gold standard in many practices, particularly for the approximately 15% of cases with failed SLN mapping.
Authors: L Lelievre; S Camatte; M A Le Frere-belda; K Kerrou; M Froissart; R Taurelle; F Vilde; F Lecuru Journal: Int J Gynecol Cancer Date: 2004 Mar-Apr Impact factor: 3.437
Authors: Michael Frumovitz; Brian M Slomovitz; Diljeet K Singh; Russell R Broaddus; Jacki Abrams; Charlotte C Sun; Michael Bevers; Diane C Bodurka Journal: J Am Coll Surg Date: 2004-09 Impact factor: 6.113
Authors: Jennifer J Mueller; Lawrence T Dauer; Rajmohan Murali; Alexia Iasonos; Neeta Pandit-Taskar; Nadeem R Abu-Rustum; Jan Grimm Journal: J Nucl Med Date: 2020-01-10 Impact factor: 10.057
Authors: Maria B Schiavone; Oliver Zivanovic; Qin Zhou; Mario M Leitao; Douglas A Levine; Robert A Soslow; Kaled M Alektiar; Vicky Makker; Alexia Iasonos; Nadeem R Abu-Rustum Journal: Ann Surg Oncol Date: 2015-05-21 Impact factor: 5.344
Authors: Elizabeth L Jewell; Juan Juan Huang; Nadeem R Abu-Rustum; Ginger J Gardner; Carol L Brown; Yukio Sonoda; Richard R Barakat; Douglas A Levine; Mario M Leitao Journal: Gynecol Oncol Date: 2014-02-28 Impact factor: 5.482
Authors: Robert W Holloway; Nadeem R Abu-Rustum; Floor J Backes; John F Boggess; Walter H Gotlieb; W Jeffrey Lowery; Emma C Rossi; Edward J Tanner; Rebecca J Wolsky Journal: Gynecol Oncol Date: 2017-05-28 Impact factor: 5.482
Authors: Christine H Kim; Fady Khoury-Collado; Emma L Barber; Robert A Soslow; Vicky Makker; Mario M Leitao; Yukio Sonoda; Kaled M Alektiar; Richard R Barakat; Nadeem R Abu-Rustum Journal: Gynecol Oncol Date: 2013-10-04 Impact factor: 5.482
Authors: Marcos Ballester; Martin Koskas; Charles Coutant; Elisabeth Chéreau; Jeremy Seror; Roman Rouzier; Emile Daraï Journal: BMC Cancer Date: 2010-08-30 Impact factor: 4.430